Humacyte, Inc.
HUMANASDAQHealthcare● Active
$1.41
+$0.06(+4.44%)
Market Cap$236880000
P/E Ratio—
52W High$2.93
52W Low$0.547
Humacyte, Inc. (HUMA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HUMA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.09
Est. -$0.10 · +10.0%
Revenue
$0.00B
Est. $0.00B · -66.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
HUMA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.10 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.10 | -$0.09 | +10.0% | $0.00B | $0.00B | -66.2% |
| — Q1 FY2026 | Mar 27, 2026 | -$0.13 | -$0.13 | +0.0% | $0.00B | $0.00B | -65.4% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.17 | -$0.14 | +17.6% | $0.00B | $0.00B | -44.2% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.15 | -$0.24 | -60.0% | $0.00B | $0.00B | -67.2% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.19 | -$0.10 | +47.4% | $0.00B | $0.00B | -32.4% |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$0.23 | -$0.16 | +30.4% | $0.01B | $0.00B | +1029.0% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.26 | -$0.33 | -26.9% | — | $0.00B | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+10.0%
Revenue
$0.00B
Q1 FY2026
Mar 27, 2026
EPS Actual
-$0.13
EPS Est.
-$0.13
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.17
EPS Surpr.
+17.6%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.15
EPS Surpr.
-60.0%
Revenue
$0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.19
EPS Surpr.
+47.4%
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.23
EPS Surpr.
+30.4%
Revenue
$0.01B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$0.33
EPS Est.
-$0.26
EPS Surpr.
-26.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.05 | $0.07 | $0.10 | 1 |
| Q3 FY2028 | $0.03 | $0.04 | $0.05 | 1 |
| Q2 FY2028 | $0.01 | $0.02 | $0.03 | 1 |
| Q1 FY2028 | $0.17 | $0.25 | $0.34 | 1 |
| Q4 FY2027 | $-0.09 | $-0.06 | $-0.04 | 1 |
| Q3 FY2027 | $-0.10 | $-0.07 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.0B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.1B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +10.0% | $0.91 | $1.13 | +24.18% |
| ▲ Q1 FY2026 | Mar 27, 2026 | +0.0% | $0.78 | $0.68 | -13.21% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +17.6% | $1.28 | $1.25 | -2.34% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -60.0% | $2.48 | $1.75 | -29.44% |
| ▲ Q2 FY2025 | May 13, 2025 | +47.4% | $1.32 | $1.73 | +31.06% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +30.4% | $2.01 | $1.96 | -2.49% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -26.9% | $5.26 | $5.78 | +9.89% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -17.4% | $6.62 | $6.65 | +0.45% |
Q2 FY2026+24.18%
Report Date
May 13, 2026
EPS Beat/Miss
+10.0%
Price Before
$0.91
Price After
$1.13
Q1 FY2026-13.21%
Report Date
Mar 27, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.78
Price After
$0.68
Q4 FY2025-2.34%
Report Date
Nov 12, 2025
EPS Beat/Miss
+17.6%
Price Before
$1.28
Price After
$1.25
Q3 FY2025-29.44%
Report Date
Aug 11, 2025
EPS Beat/Miss
-60.0%
Price Before
$2.48
Price After
$1.75
Q2 FY2025+31.06%
Report Date
May 13, 2025
EPS Beat/Miss
+47.4%
Price Before
$1.32
Price After
$1.73
Q1 FY2025-2.49%
Report Date
Mar 28, 2025
EPS Beat/Miss
+30.4%
Price Before
$2.01
Price After
$1.96
Q4 FY2024+9.89%
Report Date
Nov 8, 2024
EPS Beat/Miss
-26.9%
Price Before
$5.26
Price After
$5.78
Q3 FY2024+0.45%
Report Date
Aug 13, 2024
EPS Beat/Miss
-17.4%
Price Before
$6.62
Price After
$6.65
Avg Beat Reaction+7.44%
Avg Miss Reaction-6.37%
Beat Rate5 / 8 quarters
Largest Move+31.06% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HUMA ends December
Humacyte, Inc. (HUMA) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.09 — beating the analyst consensus of $-0.10 by +10.0%. HUMA has beaten EPS estimates for 3 consecutive quarters. The next HUMA earnings date is expected around September 1, 2026.
Each quarter, investors track HUMA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HUMA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HUMA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HUMA earnings · 5 questionsHumacyte, Inc.'s next earnings report is expected around September 1, 2026. HUMA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HUMA historically reports after market close (AMC).
HUMA earnings datewhen is HUMA earningsHUMA next earnings datewhen does HUMA report earningsHUMA earnings calendar
▸ Source: FMP · Humacyte, Inc. SEC filings · US GAAP · Humacyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026